This month, Hoosier Cancer Research Network highlights University of Washington (UW) / Fred Hutchinson Cancer Research Center and Petros Grivas, MD, PhD, a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. In 2018, Dr. Grivas joined UW School of Medicine as an associate professor in the Department of Medicine and Clinical Director of the Genitourinary Cancers Program at UW and Fred Hutchinson Cancer Center.

Dr. Grivas completed his training at the University of Patras Medical School and earned his MD degree in 2005. Following medical school, he then pursued a PhD in medical oncology under the mentorship of academic faculty and defended his thesis successfully in late 2008. He completed his residency in internal medicine at Hahnemann University Hospital/Drexel University College of Medicine in 2010. Dr. Grivas then completed his fellowship in hematology/oncology at University of Michigan in 2013. Dr. Grivas stayed at the University of Michigan as clinical lecturer for another year before he was recruited as an assistant professor at the Cleveland Clinic, where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, teaching and mentoring trainees, and taking care of patients with GU cancers.

Dr. Grivas has had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer (e.g., avelumab switch maintenance based on Javelin Bladder100, sacituzumab govitecan based on TROPHY-U-01), and is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists and other healthcare providers, mentoring trainees, leading large innovative clinical trials, reviewing grant proposals, abstracts and manuscripts, and publishing novel and important research. He is involved in the ECOG-ACRIN co-operative research group, working with the American Society of Clinical Oncology, European Society of Medical Oncology, International Bladder Cancer Group, International Bladder Cancer Network, Bladder Cancer Advocacy Network, among several other organizations. Dr. Grivas is dedicated to efficient, personalized, outstanding patient care, and believes in optimal patient-physician relationship and community outreach.

Educational Background:

• Medical School: University of Patras Medical School
• Residency: Hahnemann University Hospital/Drexel University College of Medicine, Internal Medicine
• Fellowship: University of Michigan, Hematology/Oncology

Three facts about Dr. Grivas:

• Loves to dance (different dance types/styles) and can perform solo and group Greek dancing
• Adores reading poetry, history and philosophy, also writes poetry occasionally
• Played basketball in a team for about a decade, mainly during adolescence

About Hoosier Cancer Research Network

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.